Related Experiment Video

Updated: Oct 5, 2025

Assessment of Kidney Function in Mouse Models of Glomerular Disease
09:16

Assessment of Kidney Function in Mouse Models of Glomerular Disease

Published on: June 30, 2018

17.9K

SGLT2 inhibitors in non-diabetic kidney disease

Vladimír Tesař1

  • 1Department of Nephrology, Charles University in Prague, Czech Republic.

Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University
|January 25, 2022
PubMed

Insights

Sodium-glucose cotransporter 2 (SGLT2) inhibitors, like dapagliflozin, show renoprotective effects in chronic kidney disease, even without diabetes. Their benefits are enhanced when combined with renin-angiotensin system blockers.

Area of Science:

  • Nephrology
  • Pharmacology
  • Cardiology

Background:

  • Accumulating evidence supports the renoprotective and cardioprotective roles of sodium-glucose cotransporter 2 (SGLT2) inhibitors in diabetic kidney disease.
  • The Dapagliflozin and Prevention of Adverse Outcomes in the Chronic Kidney Disease (DAPA-CKD) trial demonstrated dapagliflozin's renoprotective efficacy in non-diabetic chronic kidney disease across a broad range of estimated glomerular filtration rates (eGFR) and albumin/creatinine ratios.

Discussion:

  • Dapagliflozin exhibited renoprotective effects in non-diabetic chronic kidney disease patients, irrespective of diabetes status.
  • While specific conditions like type 1 diabetes, autosomal dominant polycystic kidney disease, ANCA-associated vasculitis, and lupus nephritis were excluded, subanalyses suggested potential benefits in IgA nephropathy.
  • The renoprotective impact of SGLT2 inhibitors is additive to that of renin-angiotensin system blockers, including ACE inhibitors (ACEI) and angiotensin receptor blockers (ARB).

Key Insights:

  • SGLT2 inhibitors offer renoprotection in chronic kidney disease (CKD) beyond diabetic nephropathy.
  • Dapagliflozin demonstrated efficacy in non-diabetic CKD patients with varying eGFR and albuminuria levels.
  • Combined therapy with SGLT2 inhibitors and RAS blockers provides additive renoprotection.

Outlook:

  • Further confirmation is anticipated from the ongoing Study of Heart and Kidney Protection With Empagliflozin (EMPA-KIDNEY) trial.
  • These findings may expand the therapeutic applications of SGLT2 inhibitors in kidney disease management.
  • Continued research will elucidate the full potential of SGLT2 inhibitors in diverse CKD populations.
Keywords:
SGLT2 inhibitorchronic kidney diseasedapagliflozin

More Related Videos

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

345
5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

23.8K

Related Concept Videos

Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
280
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
328
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
75
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
290
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
96
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
877